Speed, Evidence, and Safety Characteristics of Vaccine Approvals by the US Food and Drug Administration

被引：17

作者：

Puthumana, Jeremy ^{[1
]}

Egilman, Alexander C. ^{[2
]}

Zhang, Audrey D. ^{[3
]}

Schwartz, Jason L. ^{[4
]}

Ross, Joseph S. ^{[1
,2
,4
]}

机构：

[1] Yale Sch Med, Dept Internal Med, New Haven, CT USA

[2] Yale New Haven Med Ctr, Ctr Outcomes Res & Evaluat, 20 York St, New Haven, CT 06504 USA

[3] Duke Univ, Sch Med, Dept Med, Durham, NC 27706 USA

[4] Yale Sch Publ Hlth, Dept Hlth Policy & Management, New Haven, CT USA

来源：

关键词：

D O I：

10.1001/jamainternmed.2020.7472

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

This cross-sectional study evaluates all of the novel vaccines approved by the US Food and Drug Administration over the last decade.

引用

页码：559 / 560

页数：2

共 4 条

[1] Associated Press-NORC Center for Public Affairs, EXPECTATIONS COVID 1
[2] Regulatory Decision-making on COVID-19 Vaccines During a Public Health Emergency
Avorn, Jerry
Kesselheim, Aaron
[J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2020, 324 (13): : 1284 - 1285
[3] Clinical Trial Evidence Supporting FDA Approval of Novel Therapeutic Agents, 2005-2012
Downing, Nicholas S.
Aminawung, Jenerius A.
Shah, Nilay D.
Krumholz, Harlan M.
Ross, Joseph S.
[J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2014, 311 (04): : 368 - 377
[4] US Food and Drug Administration, BIOLOGICAL APPROVALS